[Drawn towards a career in elderly care medicine, but not till after medical school. Elderly care medicine as a career choice].

A. Meiboom,H. de Vries,B. Hesselink,C. Hertogh,F. Scheele

DOI: https://doi.org/10.1007/s12439-013-0056-y

Tijdschrift voor Gerontologie en Geriatrie

Abstract:

What problem does this paper attempt to address?

Synthesis, enzyme inhibition assay, and molecular modeling study of novel pyrazolines linked to 4-methylsulfonylphenyl scaffold: antitumor activity and cell cycle analysis

Alaa A.-M. Abdel-Aziz,Adel S. El-Azab,Simone Brogi,Rezk R. Ayyad,Hamad M. Alkahtani,Hatem A. Abuelizz,Ibrahim A. Al-Suwaidan,Abdulrahman M. Al-Obaid

DOI: https://doi.org/10.1039/d4ra03902e

IF: 4.036

2024-07-13

RSC Advances

Abstract:Antitumor activity using 59 cancer cell lines and enzyme inhibitory activity of a newly synthesized pyrazoline-linked 4-methylsulfonylphenyl scaffold (compounds 18a–q ) were measured and compared with those of standard drugs. Pyrazolines 18b , 18c , 18f , 18g , 18h , and 18n possessed significant antitumor activity, with a positive cytotoxic effect (PCE) of 22/59, 21/59, 21/59, 48/59, 51/59, and 20/59, respectively. The cancer cell lines HL60, MCF-7, and MDA-MB-231 were used to measure the IC 50 values of derivatives 18c , 18g , and 18h via the MTT assay method, and the results were compared with those of reference drugs. Derivatives 18g and 18h showed potent and broad-spectrum antitumor activities against HL60 (IC 50 of 10.43, 8.99 μM, respectively), MCF-7 (IC 50 of 11.7 and 12.4 μM, respectively), and MDA-MB-231 (IC 50 of 4.07 and 7.18 μM, respectively). Compound 18c exhibited strong antitumor activity against HL60 and MDA-MB-231 cell lines with IC 50 values of 8.43 and 12.54 μM, respectively, and moderate antitumor activity against MCF-7 cell lines with an IC 50 value of 16.20 μM. Compounds 18c , 18g , and 18h remarkably inhibited VEGFR2 kinase (IC 50 = 0.218, 0.168, and 0.135 μM, respectively) compared with the reference drug sorafenib (IC 50 = 0.041 μM). Compounds 18g and 18h effectively inhibited HER2 kinase (IC 50 = 0.496 and 0.253 μM, respectively) compared with erlotinib (IC 50 = 0.085 μM). Compound 18h inhibited EGFR kinase (IC 50 = 0.574 μM) with a potency comparable with that of the reference drug erlotinib (IC 50 = 0.105 μM). Pyrazolines 18c , 18f , and 18h arrested the S/G2 phase of the cell cycle in HL-60 cells. In addition, derivatives 18c , 18f , and 18h revealed lower Bcl-2 protein expression anti-apoptotic levels and higher Bax, caspase-3, and caspase-9 expression levels. Molecular docking studies of derivative 18h into the binding sites of EGFR, HER2, and VEGFR2 kinases explored the interaction mode of these pyrazoline derivatives and their structural requirements for antitumor activity.

chemistry, multidisciplinary
Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Ju Hou,Shanhe Wan,Guangfa Wang,Tingting Zhang,Zhonghuang Li,Yuanxin Tian,Yonghuan Yu,Xiaoyun Wu,Jiajie Zhang

DOI: https://doi.org/10.1016/j.ejmech.2016.04.026

IF: 7.088

2016-01-01

European Journal of Medicinal Chemistry

Abstract:Three series of novel quinazoline and pyrido[2,3-d]pyrimidine derivatives were designed, synthesized and evaluated for their ability to inhibit EGFR tyrosine kinase and a panel of five human cancer cell lines (MCF-7, A549, BT-474, SK-BR-3, and MDA-MB-231). Bioassay results indicated that five of these prepared compounds (12c-12e and 13c-13d) exhibited remarkably higher inhibitory activities against EGFR and SK-BR-3 cell line. Compounds 12c and 12e displayed the most potent EGFR inhibitory activity (IC50 = 2.97 nM and 3.58 nM, respectively) and good anti-proliferative effect against SK-BR-3 cell with the IC50 values of 3.10 mu M and 5.87 mu M, respectively. Furthermore, molecular docking and molecular dynamics simulation studies verified that compound 12c and 12e shared similar binding pattern with gefitinib in the binding pocket of EGFR. MM-GBSA binding free energy revealed that the compound 12c and 12e have almost the same inhibitory activity against EGFR as gefitinib, and that the dominating effect of van der Waals interactions drives the binding process. (C) 2016 Elsevier Masson SAS. All rights reserved.
Pyridine-based glycosides bearing 1,2,4-triazole and their 1,3,4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: Design, synthesis, antiproliferative activity and in silico studies

Asmaa F. Kassem,Ahmed Younis,Eman S. Nossier,Hanem M. Awad,Wael A. El-Sayed

DOI: https://doi.org/10.1016/j.molstruc.2024.138741

IF: 3.841

2024-05-29

Journal of Molecular Structure

Abstract:The increasing toxicity of recently developed anticancer medications is seen as a serious problem that stems from the variety of targets involved; as a result, more research on these phenomena is necessary. In the present work, a novel class of pyridine-based glycosides with a 1,2,4-triazole core and their 1,3,4-oxadiazolyl counterparts with distinct sugar segments are designed and synthesized. The afforded products were studied for their cytotoxicity behavior against a number of cell lines of human cancer. Pyridine-based glycosides 14 and 21 revealed excellent anticancer activity against HepG-2 and MCF-7 cell lines (IC 50 = 10.6, 12.8 μM against HepG-2 and 8.3, 9.8 μM against MCF-7, respectively). The inhibitory investigation of the latter promising candidates was further examined in against CDK-2/cyclin A2 kinases and EGFR. The 1,2,4-triazole glycoside-based pyridine system and its oxadiazolyl analog were approximately equipotent with the reference erlotinib in the inhibitory activity against EGFR. On the other hand, the pyridine-1,3,4-oxadiazole product 21 explored a higher potency and sensitivity (half the potency of roscovitine) against CDK-2/cyclin A2 than its pyridine-1,2,4-triazole analogue 14 . In an effort to understand its mode of action, it was also investigated how oxadiazolyl-glycoside 21 affected the induction of apoptosis and cell cycle arrest. Furthermore, it increased the MCF-7 cells' p53 and, Bax levels. To further obtain a clear justification and acquire knowledge of the binding nature and affinities of the potent compounds and their targeted enzymes, a molecular docking investigation was simulated. This promotes the deployment of the compounds as effective leads for future investigations in anticancer research.

chemistry, physical
S‐inequality for certain product measures

P. Nayar,T. Tkocz

DOI: https://doi.org/10.1002/mana.201200294

2012-10-19

Abstract:In this paper we prove the S‐inequality for certain product probability measures and ideals in Rn . As a result, for the Weibull and Gamma product distributions we derive concentration of measure type estimates as well as optimal comparison of moments.
Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors

Reinad R Abu Rabah,Anusha Sebastian,Srinivasulu Vunnam,Shaista Sultan,Hamadeh Tarazi,Hanan S Anbar,Mahmoud K Shehata,Seyed-Omar Zaraei,Sara M Elgendy,Salma A Al Shamma,Hany A Omar,Taleb H Al-Tel,Mohammed I El-Gamal

DOI: https://doi.org/10.1016/j.bmc.2022.116894

2022-09-01

Abstract:The design, synthesis, and biological activities of a new series of pyrazole derivatives are reported. The target compounds 1a-1w were initially investigated against NCI-60 cancer cell lines. Compounds 1f, 1h, 1k, and 1v exerted the highest anti-proliferative activity over the studied panel of cancer cell lines. Compound 1f showed the most potent activity, and it is more potent than sorafenib in 29 cancer cell lines of different types and more potent than SP600125 against almost all the tested cancer cell lines. It also exerted sub-micromolar IC50 values (0.54-0.98 µM) against nine cell lines. Moreover, the 23 target compounds were tested against Hep3B and HepG2 hepatocellular carcinoma cell lines, of which compounds 1b, 1c, and 1h showed the strongest anti-proliferative activity. The most potent anticancer compounds (1b, 1c, 1f, and 1h) demonstrated a high selectivity towards cancer cells vis-à-vis normal cells. Compounds1f and 1h induced apoptosis and mild necrosis upon testing against RPMI-8226 leukemia cells. Kinase profiling of this series led to the discovery of two potent and selective JNK3 inhibitors, compounds 1c and 1f with an IC50 values of 99.0 and 97.4 nM, respectively. Both compounds showed a good inhibitory effect against JNK3 kinase in the whole-cell NanoBRET assay. This finding was further supported through molecular modeling studies with the JNK3 binding site. Moreover, compounds 1c and 1f demonstrated a very weak activity against CYP 2D6, CYP 3A4, and hERG ion channels.
Design, synthesis, biological evaluation, in silico ADME prediction and molecular docking of pyrazole-benzamides as multitargeting protien kinase inhibitors

Nada A. Khaled,Nesreen S. Ahmed,Ahmed Z. Abdelazem,Neama A. Mohamed,Ahmed F. El-Sayed,Sayed A. Ahmed

DOI: https://doi.org/10.1016/j.molstruc.2023.135753

IF: 3.841

2023-05-17

Journal of Molecular Structure

Abstract:In the present study, N -(1-(2-bromobenzoyl)-4-cyano-1 H -pyrazol-5-yl) halogenated benzamides (5a-h) were prepared and evaluated for their in vitro anticancer activity against three cancer cell lines, namely hepatic cancer (HepG-2), breast cancer (MCF-7) and colon cancer (HCT-116). The derivatives 5a - d and 5h revealed the most promising growth inhibition effect, with IC 50 values ranging from 0.005133±0.000042 to 0.022249±0.000069 μM, compared to doxorubicin, which had IC 50 values of 0.004635±0.000002, 0.004587±0.000029, and 0.004064±0.000002 μM respectively. The potential ADME properties of 5a-h were investigated using calculations. Compounds 5a-h have good oral bioavailability and gastrointestinal absorption but cannot penetrate the blood-brain barrier. According to ADME results, 5b has a tumorigenic and reproductive effect. Furthermore, the derivatives 5a, 5b, and 5d produced promising safety profiles on the WI-38 normal cell line with IC 50 values of 0.045374±0.002593, 0.115714±0.006732, and 0.058241±0.003411 μM, respectively, compared to doxorubicin, which had IC 50 value of 0.038234±0.00223 μM. Moreover, utilizing afatinib and sorafenib as positive controls, compounds 5a, 5b , and 5d were further assessed as in vitro multitargeting candidates towards EGFR WT , VEGFR-2, and B-RAF WT . For the purpose of figuring out potential ligand-protien interactions and stability, in silico molecular docking simulations against VEGFR-2, EGFR WT , and B-RAF WT were run. The results exhibited that compound 5b was the most potent compound, producing an inhibition effect on EGFR WT and B-RAF WT kinases that was approximately equipotent to that obtained by the reference drugs afatinib and sorafenib with IC 50 values of 0.000140±0.000009 and 0.000158±0.000009 μM, respectively (IC 50 Afatinib : 0.000086±0.000004, IC 50 Sorafenib : 0.000097±0.000006) The molecular docking study confirmed the biological result. Moreover, compound 5b arrested the HCT-116 cell cycle at the G1/S phase and showed a good early and late apoptotic induction effect within HCT-116 cells.

chemistry, physical
Design, synthesis and in vitro anti-proliferative evaluation of new pyridine-2,3-dihydrothiazole/thiazolidin-4-one hybrids as dual CDK2/GSK3β kinase inhibitors

Asmaa F Kassem,Ashraf A Sediek,Mervat M Omran,Doaa S Foda,Aisha A K Al-Ashmawy

DOI: https://doi.org/10.1039/d4ra06146b

2024-10-07

Abstract:Herein, the molecular hybridization drug discovery approach was used in the design and synthesis of twelve novel pyridine-2,3-dihydrothiazole hybrids (2a,b-5a,b and 13a,b-14a,b) and fourteen pyridine-thiazolidin-4-one hybrids (6a,b-12a,b) as anti-proliferative analogues targeting CDK2 and GSK3β kinase inhibition. Almost all of the newly synthesized hybrids, including their precursors (1a,b), were evaluated for their anti-proliferative activity against three human cancer cell lines-MCF-7, HepG2 and HEp-2-as well as normal Vero cell lines. Both compounds 1a (pyridine-thiourea precursor) and 8a (pyridine-5-acetyl-thiazolidin-4-one hybrid) exhibited excellent anti-proliferative activity against HEp-2 (IC50 = 7.5 μg mL-1, 5.9 μg mL-1, respectively). Additionally, 13a (pyridine-5-(p-tolyldiazenyl-2,3-dihydrothiazole)) hybrid demonstrated excellent anti-proliferative activity against HepG2 (IC50 = 9.5 μg mL-1), with an acceptable safety profile against Vero (<45% inhibition at 100 μg mL-1) in the cases of 8a and 13a alone. The three promising anti-proliferative hybrids (1a, 8a, 13a) were selected for the assessment of their in vitro inhibitory kinase activity against CDK2/GSK3β using roscovitine (IC50 = 0.88 μg mL-1) and CHIR-99021 (IC50 = 0.07 μg mL-1) as references, respectively. Compound 13a was the most potent dual CDK2/GSK3β inhibitor (IC50 = 0.396 μg mL-1, 0.118 μg mL-1, respectively) followed by 8a (IC50 = 0.675 μg mL-1, 0.134 μg mL-1, respectively), and the weakest was 1a. To elucidate the mechanism of the most potent anti-proliferative 13a hybrid, further cell cycle analysis was performed revealing that it caused G1 cell cycle arrest and induced apoptosis. Moreover, it resulted in an increase in Bax and caspase-3 with a decrease in Bcl-2 levels in HepG2 cells compared with untreated cells. Finally, in silico drug likeness/ADME prediction for the three potent compounds as well as a molecular docking simulation study were conducted in order to explore the binding affinity and interactions in the binding site of each enzyme, which inspired their usage as anti-proliferative leads for further modification.
Design, synthesis, and in vitro and in vivo biological evaluation of triazolopyrimidine hybrids as multitarget directed anticancer agents

Heba A. Adawy,Samar S. Tawfik,Abdullah A. Elgazar,Khalid B. Selim,Fatma E. Goda

DOI: https://doi.org/10.1039/d4ra06704e

IF: 4.036

2024-11-09

RSC Advances

Abstract:In response to the urgent need for new anti-proliferative agents, four novel series of triazolopyrimidine compounds ( 7a–e , 9a–d , 11a–f , and 13a–e ) were synthesized and evaluated for in vitro anticancer efficacy against HCT116, HeLa, and MCF-7 cell lines. Compound 13c emerged as the most potent, with IC 50 values of 6.10, 10.33, and 2.42 μM respectively, while 11e and 7c also showed strong activity. In multi-target suppression tests, 13c exhibited the highest inhibition against EGFR, TOP-II, HER-2, and ARO (IC 50 : 0.087, 31.56, 0.078, and 0.156 μM, respectively). Flow cytometry revealed 13c 's ability to suppress the S-phase cell population in MCF-7 cells. In vivo studies of 13c demonstrated significant tumor growth inhibition, comparable to the positive control. Molecular docking studies supported the experimental findings, confirming the binding of the novel motifs to the target enzymes' active sites. This comprehensive evaluation highlights the potential of these triazolopyrimidine compounds, particularly 13c , as promising anticancer agents, warranting further investigation.

chemistry, multidisciplinary
Synthesis of a new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors

Lamya H Al-Wahaibi,Bahaa G M Youssif,Hesham A Abou-Zied,Stefan Bräse,Alan B Brown,Hendawy N Tawfeek,Essmat M El-Sheref

DOI: https://doi.org/10.1039/d4md00230j

2024-06-24

Abstract:The current study focuses on developing a single molecule that acts as an antiproliferative agent with dual or multi-targeted action, reducing drug resistance and adverse effects. A new series of 4-pyrazolylquinolin-2-ones (5a-j) with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors were designed and synthesized. Compounds 5a-j were investigated for their cell viability effect against a normal cell line (MCF-10A). Results showed that none of the compounds were cytotoxic, and all 5a-j demonstrated more than 90% cell viability at 50 μM concentration. Using erlotinib as a reference, the MTT assay investigated the antiproliferative impact of targets 5a-j against four human cancer cell lines. Compounds 5e, 5f, 5h, 5i, and 5j were the most potent antiproliferative agents with GI50 values of 42, 26, 29, 34, and 37 nM, making compounds 5f and 5h more potent than erlotinib (GI50 = 33 nM). Moreover, compounds 5e, 5f, 5h, 5i, and 5j were further investigated as dual EGFR/BRAFV600E inhibitors, and results revealed that compounds 5f, 5h, and 5i are potent antiproliferative agents that act as dual EGFR/BRAFV600E inhibitors. Cell cycle analysis and apoptosis detection revealed that compound 5h displaying cell cycle arrest at the G1 transition could induce apoptosis with a high necrosis percentage. Docking studies revealed that compound 5f exhibited a strong affinity for EGFR and BRAFV600E, with high docking scores of -8.55 kcal mol-1 and -8.22 kcal mol-1, respectively. Furthermore, the ADME analysis of compounds 5a-j highlighted the diversity in their pharmacokinetic properties, emphasizing the importance of experimental validation.
Design and synthesis of new indole containing biaryl derivatives as potent antiproliferative agents

Shuo Yuan,Si-Qi Feng,An-Qi Li,Jia-Hui Zuo,Dan-Qing Zhang,Yu-Jie Xing,Zhiyu Xie,Bin Yu,Hong-Min Liu

DOI: https://doi.org/10.1016/j.bioorg.2021.104821

IF: 5.307

2021-05-01

Bioorganic Chemistry

Abstract:A new series of indole containing biaryl derivatives were designed and synthesized, and further biological evaluations of their antiproliferative activity against cancer cell lines (MGC-803 and TE-1 cells) were also conducted. Of these synthesized biaryls, compound 4-methyl-2-((5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)methyl)quinazoline (23) performed as the most potent antiproliferative agent that inhibited cell viability of MGC-803 cells with an IC50 value of 8.28 µM. In addition, investigation of mechanism exhibited that the compound 4-methyl-2-((5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)methyl)quinazoline (23) could inhibit the expression of c-Myc and glycolysis related proteins, decrease the ATP and lactate production, and further induce apoptosis by activating the AMP-activated protein kinase (AMPK) and p53 signaling pathways.

biochemistry & molecular biology,chemistry, organic
Approaches to Preventing Peritonitis Based on Organism-Specific Rates

B. Piraino

DOI: https://doi.org/10.3747/pdi.2011.00273

2011-11-01

Peritoneal Dialysis International

Abstract:This issue of Peritoneal Dialysis International contains an important paper from a work group of the International Society for Peritoneal Dialysis (ISPD) (1). Their long-awaited paper addresses the prevention of peritonitis in adults. Many months of labor went into the manuscript, which was assembled by a team of experts from around the world. Together with the 2010 infections recommendations in adults (2), the new paper sets out current knowledge about peritonitis in patients on peritoneal dialysis (1). The hope is that both papers will be widely used to improve outcomes in patients on peritoneal dialysis within various programs. In addition, the journal editor has included two closely related papers that present detailed reports on peritonitis rates from two countries (3,4). A registry report from Australia presents peritonitis data covering 63 months and 6639 patients over a total of 10 382 years at risk, and a paper from Scotland covers peritonitis data for 96 months and 3175 years at risk. Such data are critical, providing platforms of knowledge upon which to build change. Table 1 in the present article organizes peritonitis rates abstracted from the Australian and Scottish papers as organism-specific rates. For the purposes of comparison of the two databases, I converted months
Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors

Amany Belal,Nagwa M. Abdel Gawad,Ahmed B. M. Mehany,Mohammed A. S. Abourehab,Hazem Elkady,Ahmed A. Al‐Karmalawy,Ahmed S. Ismael

DOI: https://doi.org/10.1080/14756366.2022.2096019

2022-07-08

Journal of Enzyme Inhibition and Medicinal Chemistry

Abstract:A new series of 1 H -pyrrole ( 6a–c , 8a–c ), pyrrolo[3,2- d ]pyrimidines ( 9a–c ) and pyrrolo[3,2- e ][1, 4]diazepines ( 11a–c ) were designed and synthesised. These compounds were designed to have the essential pharmacophoric features of EGFR Inhibitors, they have shown anticancer activities against HCT116, MCF-7 and Hep3B cancer cells with IC 50 values ranging from 0.009 to 2.195 μM. IC 50 value of doxorubicin is 0.008 μM, compounds 9a and 9c showed IC 50 values of 0.011 and 0.009 μM respectively against HCT-116 cells. Compound 8b exerted broad-spectrum activity against all tested cell lines with an IC 50 value less than 0.05 μM. Compound 8b was evaluated against a panel of kinases. This compound potently inhibited CDK2/Cyclin A1, DYRK3 and GSK3 alpha kinases with 10–23% compared to imatinib (1–10%). It has also arrested the cell cycle of MCF-7 cells at the S phase. Its antiproliferative activity was further augmented by molecular docking into the active sites of EGFR and CDK2 cyclin A1.

biochemistry & molecular biology,chemistry, medicinal
Novel pyrano[2,3-c]pyrazolopyrimidines as promising anticancer agents: Design, synthesis, and cell cycle arrest of HepG2 cells at S phase

David S. A. Haneen,Mohamed H. Hekal,Wael S. I. Abou-Elmagd,Wael M. El-Sayed

DOI: https://doi.org/10.1080/00397911.2024.2327047

2024-03-12

Synthetic Communications

Abstract:The poor selectivity, significant toxicity, high cost, and emergence of resistance of conventional chemotherapies are driving motive for the ongoing search for novel anticancer agents. New pyrano[2,3- c ]pyrazolopyrimidines were synthesized and examined as antiproliferative agents, and the possible molecular mechanism(s) of action were explored. The mass and elemental analyses, alongside the IR, 1 H, and 13 C NMR spectra, confirmed the proposed structures of the obtained compounds. Derivatives 4 and 7 demonstrated the best antiproliferative profile against HepG2 cancer cells at 4 μM, with a high selectivity index of ∼7–9 folds. They increased the S phase cell population by 51% and 40% and caused a 5- and 11-fold increase in the p21 protein. Compound 7 was superior in inhibiting HepG2 cell migration and delayed wound healing, reducing migration rates by 55% and 90%, respectively. Future studies on the pharmacokinetics, pharmacodynamics, antimetastatic, and antitumor activities in animal models would be a robust advance.

chemistry, organic
Molecular docking, DFT and antiproliferative properties of 4‐(3,4‐dimethoxyphenyl)−3‐(4‐methoxyphenyl)−1‐phenyl‐1H‐pyrazolo[3,4‐b]pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency

Faizah A. Binjubair,Basma S. Almansour,Noha I. Ziedan,Alaa A.‐M. Abdel‐Aziz,Sara T. Al‐Rashood,Mohamed K. Elgohary,Mahmoud S. Elkotamy,Hatem A. Abdel‐Aziz

DOI: https://doi.org/10.1002/ddr.70009

2024-10-29

Drug Development Research

Abstract:Due to the limited effeteness and safety concerns associated with current cancer treatments, there is a pressing need to develop novel therapeutic agents. 4‐(3,4‐Dimethoxyphenyl)−3‐(4‐methoxyphenyl)−1‐phenyl‐1H‐pyrazolo[3,4‐b]pyridine (3) was synthesized and Initially screened on 59 cancer cell lines showed promising anticancer activity, so, it was chosen for a 5‐dose experiment by the NCI/USA. The GI50 values ranged from 1.04 to 8.02 μM on the entire nine panels (57 cell lines), with a GI50 of 2.70 μM for (MG‐MID) panel, indicating an encouraging action. To further explore the molecular attributes of compound 3, we optimized its structure using DFT with the B3LYP/6‐31 + + G(d,p) basis set. We have considered vibrational analysis, bond lengths and angles, FMOs, and MEP for the structure. Additionally, pharmacokinetic assessments were conducted using various in‐silico platforms to evaluate the compound safety. A molecular modeling study created a kinase profile on 44 different kinases. This allowed us to study our compound's binding affinity to these kinases and compare it to the co‐crystallized one. Our findings revealed compound 3 exhibited better binding for half of the tested kinases, suggesting its potential as a multi‐kinase inhibitor. To further validate our computational results, we tested compound 3 for its inhibitory effects on CDK2 and PIM1. Compound 3 exhibited an IC50 of 0.30 μM for CDK2 inhibition, making it five times less active than Roscovitine, which has an IC50 of 0.06 μM. However, compound 3 demonstrated slightly better inhibition of PIM1 compared to Staurosporine. These findings suggest that compound 3 is a promising anticancer agent with the potential for further development into a highly active compound.

pharmacology & pharmacy,chemistry, medicinal
Characterization of dibromopolychlorodibenzo-p-dioxins and dibromopolychlorodibenzofurans in municipal waste incinerator fly ash using gas chromatography/mass spectrometry.

Le‐Qun Huang,H. Tong,J. R. Donnelly

DOI: https://doi.org/10.1021/AC00033A013

IF: 7.4

1992-05-01

Analytical Chemistry

Abstract:Several fly ash samples from different countries were analyzed for dibromopolychlorodibenzo-p-dioxins and -dibenzofurans (DBPCDD/Fs) using capillary column gas chromatography/high-resolution mass spectrometry. Concentrations of these compounds ranged from low to high parts-per-trillion (pptr) depending on the location where the samples were collected. The mass spectrometer, operated at greater than 10,000 mass resolution in combination with the high resolving power of capillary column GC, permitted characterization of DBPCDD/Fs in municipal waste incinerator fly ash for the first time. The isomer patterns of tetra- through octa-congener groups of DBPCDD/Fs are remarkably similar regardless of where the fly ash originated, indicating common mechanisms of formation of these compounds in the incinerators.
Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3- b]pyridazine derivatives as dual c-Met/Pim-1 potential inhibitors with antitumor activity

Mohamed E Mahmoud,Eman M Ahmed,Hamdy M Ragab,Rania Farag A Eltelbany,Rasha A Hassan

DOI: https://doi.org/10.1039/d4ra04036h

2024-09-24

Abstract:Interest has been piqued in c-Met and Pim-1, potential new cancer treatment targets. A variety of triazolo[4,3-b]pyridazine derivatives were synthesized to create powerful dual c-Met/Pim-1 inhibitors having the pharmacophoric elements of both enzyme inhibitors. All derivatives were screened for their cytotoxic effects on 60 cancer cell lines. Compounds 4g and 4a, had strong antiproliferative cytotoxic impacts on tumor cells, with mean GI% values of 55.84 and 29.08%, respectively. Research revealed that 4g has more powerful inhibitory activity against c-Met and Pim-1, with IC50 of 0.163 ± 0.01 and 0.283 ± 0.01 μM, respectively than the reference and derivative 4a. Moreover, compound 4g was the subject of an additional investigation into biological processes. The findings showed that compound 4g caused MCF-7 cells to arrest in the S stage of the cell cycle. Also, it accelerated the progress of apoptosis 29.61-fold more than the control. Compound 4g demonstrated a significantly higher level of caspase-9 and a decreased level of p-PI3K, p-AKT, and p-mTOR compared to staurosporine. Later, analysis of 4g showed good drug-ability and pharmacokinetic properties. A similar mode of interaction at the ATP-binding site of c-Met and Pim-1 compared to the docked ligands was suggested by additional docking studies of compound 4g.
Design, synthesis, in silico studies, and biological evaluation of novel pyrimidine-5-carbonitrile derivatives as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers

Abdulrahman M Saleh,Hazem A Mahdy,Mohamed Ayman El-Zahabi,Ahmed B M Mehany,Mohamed M Khalifa,Ibrahim H Eissa

DOI: https://doi.org/10.1039/d3ra04182d

2023-07-24

Abstract:A novel series of pyrimidine-5-carbonitrile derivatives bearing benzylidene and hydrazone moieties with different linkers (spacers) were designed and synthesized as possible inhibitors of the vascular endothelial growth factor receptor-2 (VEGFR-2). The newly synthesized compounds were evaluated in vitro for their cytotoxic activities against two human cancer cell lines namely colon cancer (HCT-116) and breast cancer (MCF-7) using sorafenib as a standard anticancer drug. Compounds 9d, 11e, 12b, and 12d showed higher cytotoxic activities than sorafenib with IC50 values ranging from 1.14 to 10.33 μM. In particular, compound 11e exhibited excellent activities against HCT-116 and MCF-7 with IC50 values of 1.14 and 1.54 μM, respectively. Moreover, compound 11e exhibited about 47.32-fold cytotoxic activity against normal human fibroblast (WI-38) cells, lower than the cytotoxicity against the cancer cells. Compounds 11e and 12b were the most potent VEGFR-2 inhibitors with IC50 values of 0.61 and 0.53 μM, respectively, compared to sorafenib. Bedsides, compound 11e arrested the HCT-116 cell growth at S and sub-G1 phases, induced a significant increase in the apoptotic cells, and caused remarkable decrease in the levels of TNF-α, IL-6, and caspase-3. Finally, the binding patterns of the target derivatives were investigated through the docking study against the proposed molecular target (VEGFR-2, PDB ID 1YWN). The results of molecular docking studies showed similar binding modes to sorafenib against VEGFR-2. In addition, molecular dynamic simulations revealed the stability of compound 11e in the active site for 100 ns.
Design, synthesis, and antiproliferative activities of novel substitutedhydrazone/triazolo-linked quinazoline derivatives

Afaf El-Malah,Azizah M. Malebari,Ahdab N. Khayyat,Khadijah A. Mohammad,Magdy M. Gineinah,Zeinab Mahmoud

DOI: https://doi.org/10.1016/j.molstruc.2024.137822

IF: 3.841

2024-02-29

Journal of Molecular Structure

Abstract:A series of novel hydrazonoquinazolines and triazoloquinazolines analogues of Erlotinib were synthesized and evaluated for their antiproliferative as well as EGFR kinase inhibitory activities. Most of the quinazoline compounds showed significant antiproliferative against different cancer cells. Among these, both compounds 4b and 5b were the best members of all the tested cancer cell lines with IC 50 in the range 1.25–4.92 μM and 1.95–7.60 μM, respectively ( c.f . erlotinib (IC 50 7.52–16.02 μM) and inhibited EGFR with IC 50 0.80 and 0.66 μM, sequentially. Additionally, these two compounds effectively induced cell cycle arrest and triggered apoptosis in HL-60 cancer cells by regulating the pro-apoptotic protein BAX and anti-apoptotic protein Bcl-2 expression. The docking studies revealed that there are interactions like that of erlotinib at the EGFR active site. In conclusion, the synthesized quinazoline compounds 4b and 5b effectively inhibit EGFR. Such a finding can be sited as a good starting point for the development of novel antitumor compounds targeting EGFR kinase.

chemistry, physical
Convenient one-pot synthesis and biological evaluation of novel 3,5-dimethyl-1H-pyrazole-1-carbothiohydrazide derivatives as new anti-tumor agents against both liver carcinoma (HepG2) and lung carcinoma (A549) cell lines

Marwa Fouad,Mahmoud Elaasser

DOI: https://doi.org/10.26434/chemrxiv-2023-dkr1h

2023-12-22

Abstract:Pyrazle constituents have garnered consideration mainly because of their presumed biological and curative properties. Therefore, the goal of the presented research is to create some novel pyrazole-1-carbothiohydrazide derivatives with predicted biological functions using an accessible one-pot synthesis employing 3,5-dimethyl-1H-pyrazole-1-carbothiohydrazide (1) as a facile antecedent. The component 1 and 1,3-diphenylpropane-1,3-dione (2) interacted resulting in pyrazole derivative 3 when ethanol or acetic acid were supplied. However, when the substance 1 interacted in ethanol with either 2 or acetyl acetone 5, using the catalytic proportion of triethylamine offered, it yielded compounds 4 and 6 respectively. Ingredient 1 was subjected to additional reactions with ethyl cyanoacetate (7), stearic acid 10, or equivalent carboxylic acids 12a-c, resulted in the formation of 9, 11, and 13a-c consequently. Additionally, when 1 was combined with α-haloketones 14 or 16, it yielded the corresponding 1,3,4-thiadiazine derivatives, 15 and 17. Every designed product's chemical structure was established according to spectroscopic and analytical results. The cytotoxic activities of the synthesized chemicals were assessed against two carcinoma cell lines, and compared to the standard drug Cisplatin using the colorimetric MTT assay. Furthermore, the results revealed that chemical 17 was the most active against the liver and lung carcinoma cell lines giving potent IC50 value of 5.35 and 8.74 μM, respectively, compared with reference drug cisplatin (3.78 and 6.39 μM). Interestingly, ingredient 17 when evaluated for their toxicity against normal lung fibroblast (MRC-5) cells exhibited low toxic effects indicating the safe use. Generally, our results exerted promising bioactive compounds.

Chemistry
New oxadiazole and pyrazoline derivatives as anti-proliferative agents targeting EGFR-TK: design, synthesis, biological evaluation and molecular docking study

Marwa I. Serag,Samar S. Tawfik,Sahar M. I. Badr,Hassan M. Eisa

DOI: https://doi.org/10.1038/s41598-024-55046-0

IF: 4.6

2024-03-07

Scientific Reports

Abstract:Two new series of oxadiazole and pyrazoline derivatives were designed and synthesized as promising EGFR-TK inhibitors. The in vitro antiproliferative activity was studied against three human cancer cell lines; HCT116, HepG-2 and MCF7 using MTT assay. Compound 10c showed the most potent anticancer activity against all cancer cell lines, with IC 50 range of 1.82 to 5.55 μM, while proving safe towards normal cells WI-38 (IC 50 = 41.17 μM) compared to the reference drug doxorubicin (IC 50 = 6.72 μM). The most active candidates 5a, 9b, 10a, 10b and 10c were further assessed for their EGFR-TK inhibition. The best of which, compounds 5a and 10b showed IC 50 of 0.09 and 0.16 μM respectively compared to gefitinib (IC 50 = 0.04 μM). Further investigation against other EGFR family members, showed that 5a displayed good activities against HER3 and HER4 with IC 50 values 0.18 and 0.37 μM, respectively compared to gefitinib (IC 50 = 0.35 and 0.58 μM, respectively). Furthermore, 5a was evaluated for cell cycle distribution and apoptotic induction on HepG-2 cells. It induced mitochondrial apoptotic pathway and increased accumulation of ROS. Molecular docking study came in agreement with the biological results. Compounds 5a and 10b showed promising drug-likeness with good physicochemical properties.

multidisciplinary sciences

[Drawn towards a career in elderly care medicine, but not till after medical school. Elderly care medicine as a career choice].

Synthesis, enzyme inhibition assay, and molecular modeling study of novel pyrazolines linked to 4-methylsulfonylphenyl scaffold: antitumor activity and cell cycle analysis

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Pyridine-based glycosides bearing 1,2,4-triazole and their 1,3,4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: Design, synthesis, antiproliferative activity and in silico studies

S‐inequality for certain product measures

Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors

Design, synthesis, biological evaluation, in silico ADME prediction and molecular docking of pyrazole-benzamides as multitargeting protien kinase inhibitors

Design, synthesis and in vitro anti-proliferative evaluation of new pyridine-2,3-dihydrothiazole/thiazolidin-4-one hybrids as dual CDK2/GSK3β kinase inhibitors

Design, synthesis, and in vitro and in vivo biological evaluation of triazolopyrimidine hybrids as multitarget directed anticancer agents

Synthesis of a new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors

Design and synthesis of new indole containing biaryl derivatives as potent antiproliferative agents

Approaches to Preventing Peritonitis Based on Organism-Specific Rates

Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors

Novel pyrano[2,3-c]pyrazolopyrimidines as promising anticancer agents: Design, synthesis, and cell cycle arrest of HepG2 cells at S phase

Molecular docking, DFT and antiproliferative properties of 4‐(3,4‐dimethoxyphenyl)−3‐(4‐methoxyphenyl)−1‐phenyl‐1H‐pyrazolo[3,4‐b]pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency

Characterization of dibromopolychlorodibenzo-p-dioxins and dibromopolychlorodibenzofurans in municipal waste incinerator fly ash using gas chromatography/mass spectrometry.

Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3- b]pyridazine derivatives as dual c-Met/Pim-1 potential inhibitors with antitumor activity

Design, synthesis, in silico studies, and biological evaluation of novel pyrimidine-5-carbonitrile derivatives as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers

Design, synthesis, and antiproliferative activities of novel substitutedhydrazone/triazolo-linked quinazoline derivatives

Convenient one-pot synthesis and biological evaluation of novel 3,5-dimethyl-1H-pyrazole-1-carbothiohydrazide derivatives as new anti-tumor agents against both liver carcinoma (HepG2) and lung carcinoma (A549) cell lines

New oxadiazole and pyrazoline derivatives as anti-proliferative agents targeting EGFR-TK: design, synthesis, biological evaluation and molecular docking study